CD8A and colorectal carcinoma: 110 MSS/pMMR advanced CRC patients after 1st-line failure; 60 in experimental group (Sintilimab + Bevacizumab), 50 in control group (FOLFIRI + Bevacizumab); 4 cycles. Evaluated CD8+ T cells, TAMs, CAFs, efficacy, and safety.